Skye Bioscience Receives Constructive Security Evaluate of SBI-100 Ophthalmic Emulsion After Second Cohort of Part 1 Research By Investing.com

Skye Bioscience, Inc. (SKYE) (“Skye” or the “Firm”), a pharmaceutical firm growing a proprietary, artificial cannabinoid by-product to deal with glaucoma, has acquired a constructive advice following a pre-specified information assessment by the security assessment committee (“SRC”) based mostly on dosing of the second cohort of eight wholesome contributors of its Part 1 examine of SBI-100 Ophthalmic Emulsion (“OE”). The SRC has really helpful that the trial proceed with out modification. Recruitment for the third cohort of eight contributors has begun, with dosing deliberate for March.

The SRC evaluated information from all eight contributors (six dosed with SBI-100 OE and two dosed with placebo) enrolled in Cohort 2 of the only ascending dose arm (“SAD”) of this Part 1 examine. On this cohort, contributors had been administered a single topical dose of SBI-100 OE at a focus of 1.0%, in comparison with a focus of 0.5% within the first cohort. Individuals had been monitored for security and tolerability over three days following dose administration. The SRC decided that, as in Cohort 1, SBI-100 OE was well-tolerated, with no drug-related critical adversarial occasions and solely delicate adversarial occasions associated to SBI-100 OE had been reported.

Within the third cohort, the dose of SBI-100 OE will enhance to a focus of two.0%.

The SRC additionally agreed to the initiation of the primary cohort of the second arm of this Part 1 examine, which is the a number of ascending dose (“MAD”) arm. This settlement can be famous within the SRC abstract which can be included in Skye’s human ethics assessment committee (“HREC”) submission to acquire approval to provoke the MAD arm of the examine.

An outline of SBI-100 Ophthalmic Emulsion and the Part 1 medical trial design may be discovered on this information launch.